君实生物：2025年归母净利润亏损8.74亿元

Core Insights - The company reported a total operating revenue of 2.498 billion yuan for the year 2025, representing a year-on-year growth of 28.23% [1] - The sales revenue of the company's core product, Toripalimab injection (brand name: Tuoyi), in the domestic market saw a significant increase of approximately 37.72% year-on-year [1] - The net profit attributable to the parent company's owners was -874 million yuan, an improvement from -1.281 billion yuan in the same period last year [1]